[A14-47] Eribulin (Addendum to Commission A14-25)
Last updated 29.01.2015
Project no.:
A14-47
Commission:
Commission awarded on 10.12.2014 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A14-25 | Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2015-01-22 A G-BA decision was published.